Results 71 to 80 of about 964 (170)

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)

International Journal of COPD, 2016
Kai-Michael Beeh,1 Eric Derom,2 José Echave-Sustaeta,3 Lars Grönke,4 Alan Hamilton,5 Dongmei Zhai,6 Leif Bjermer71Insaf GmbH Institut für Atemwegsforschung, Wiesbaden, Germany; 2Department of Internal Medicine, Ghent University Hospital,
Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L   +6 more
doaj  

First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease

International Journal of COPD, 2020
Koichiro Takahashi,1 Masaru Uchida,2 Go Kato,3 Ayako Takamori,4 Takashi Kinoshita,5 Makoto Yoshida,6 Ryo Tajiri,4 Keisuke Kojima,7 Hiroshi Inoue,8 Hiromi Kobayashi,9 Hironori Sadamatsu,1 Hiroki Tashiro,1 Masahide Tanaka,1 Shinichiro Hayashi,10 Atsushi ...
Takahashi K, Uchida M, Kato G, Takamori A, Kinoshita T, Yoshida M, Tajiri R, Kojima K, Inoue H, Kobayashi H, Sadamatsu H, Tashiro H, Tanaka M, Hayashi S, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T   +17 more
doaj  

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO® study

International Journal of COPD, 2019
Yoshiaki Minakata,1 Takashi Motegi,2 Jun Ueki,3 Yasuhiro Gon,4 Shuhei Nakamura,5 Tatsuhiko Anzai,6 Kazuto Hirata,7 Masakazu Ichinose81Department of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Wakayama, Japan; 2Department of ...
Minakata Y, Motegi T, Ueki J, Gon Y, Nakamura S, Anzai T, Hirata K, Ichinose M   +7 more
doaj  

Tioropium+Olodaterol Respimat; Budget Impact In The Uk [PDF]

Value in Health, 2015
Ternouth, A, Tebboth, A, Selya-Hammer, C, Gonzalez-Rojas Guix, N   +3 more
openaire   +2 more sources

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease

International Journal of COPD, 2015
Wijdan H Ramadan,1 Wissam K Kabbara,1 Ghada M El Khoury,1 Sarah A Al Assir21Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon; 2School of Pharmacy, Lebanese American University, Byblos, LebanonAbstract ...
Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA   +3 more
doaj  

Olodaterol in model systems of fibrosis

, 2017
published
openaire   +1 more source

The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies

International Journal of COPD, 2016
Masakazu Ichinose,1 Hiroyuki Taniguchi,2 Ayako Takizawa,3 Lars Grönke,4 Lazaro Loaiza,4 Florian Voß,4 Yihua Zhao,5 Yoshinosuke Fukuchi61Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan ...
Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y   +7 more
doaj  

New drugs: Olodaterol [PDF]

Australian Prescriber, 2014
openaire   +1 more source

Safety analysis of long-acting dual bronchodilator after market approval: a real-world study from FDA Adverse Event Reporting System (FAERS) database. [PDF]

J Thorac Dis
Gao S, Zhuang W, Song Q, Yan D, Chen L, Lai Z, Cheng Y, Yang X, Hu S.   +8 more
europepmc   +1 more source

Acute and 14-day effects of tiotropium/olodaterol on cardiopulmonary function in COPD. [PDF]

ERJ Open Res
Kayser T, Struß N, Pflock R, Heusser K, Kern AL, Voskrebenzev A, Behrendt L, Kaireit TF, Badorrek P, Tank J, Andreas S, Jordan J, Vogel-Claussen J, Hohlfeld JM.   +13 more
europepmc   +1 more source